Point72 Asset Management L.P. Cuts Stock Position in DBV Technologies S.A. (NASDAQ:DBVT)

Point72 Asset Management L.P. lessened its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 50.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,556,250 shares of the company's stock after selling 1,556,250 shares during the period. Point72 Asset Management L.P. owned 1.61% of DBV Technologies worth $1,247,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Yiheng Capital Management L.P. grew its position in shares of DBV Technologies by 6.2% in the first quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company's stock valued at $4,172,000 after purchasing an additional 327,345 shares in the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT traded up $0.01 during mid-day trading on Friday, reaching $0.69. 110,371 shares of the company were exchanged, compared to its average volume of 52,265. The firm has a market cap of $66.14 million, a price-to-earnings ratio of -0.82 and a beta of 0.68. DBV Technologies S.A. has a 1 year low of $0.50 and a 1 year high of $2.64. The firm's 50-day simple moving average is $0.84 and its 200 day simple moving average is $1.04.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same period in the previous year, the firm posted ($0.26) earnings per share. On average, research analysts forecast that DBV Technologies S.A. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on DBVT shares. StockNews.com began coverage on DBV Technologies in a research note on Friday, September 27th. They set a "hold" rating on the stock. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of DBV Technologies in a research report on Thursday, August 1st. Finally, JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.